Table 2. Initial inflammatory profile and pulmonary embolism biomarkers of patients admitted because of COVID-29 pneumonia with and without Pulmonary embolism.
| All patients (n = 30) | PE patients (n = 15) | Non-PE patients (n = 15) | p value | |
|---|---|---|---|---|
| LDH | ||||
| Baseline, U/L | 356.5 (280.3–479.8) | 376.0 (281.0–477.0) | 323.0 (268.0–611.0) | 0.724 |
| Peak, U/L | 434.0 (317.5–609.0) | 434.0 (319.0–590.0) | 434.0 (268.0–611.0) | 0.836 |
| Prior to CTPA, U/L | 341.0 (267.5–408.8) | 331.0 (281.0–393.0) | 361.0 (229.0–432.0) | 0.868 |
| CRP | ||||
| Baseline, mg/dL | 13.4 (6.0–25.4) | 10.7 (7.2–20.3) | 19.2 (5.5–26.8) | 0.604 |
| Peak, mg/dL | 18.7 (8.3–25.5) | 10.7 (7.6–21.7) | 19.2 (10.1–27.8) | 0.272 |
| Prior to CTPA, mg/dL | 2.3 (0.7–7.5) | 4.7 (1.3–9.2) | 0.9 (0.2–4.5) | 0.036 |
| ESR | ||||
| Baseline, mm/h | 67.0 (52.8–103.3) | 70.0 (55.8–101.3) | 64.0 (44.5–103.3) | 0.625 |
| Peak, mm/h | 75.5 (59.8–107.5) | 74.0 (62.0–106.8) | 77.5 (55.3–109.8) | 0.979 |
| Prior to CTPA, mm/h | 59.0 (44.0–77.3) | 64.0 (55.8–91.5) | 55.5 (30.0–69.5) | 0.173 |
| D-dimer | ||||
| Baseline, μg/mL | 0.6 (0.3–3.6) | 2.7 (0.4–10.0) | 0.3 (0.2–1.0) | 0.010 |
| Peak, μg/mL | 3.2 (2.0–9.5) | 3.4 (2.6–11.2) | 2.3 (1.6–7.3) | 0.065 |
| Prior to CTPA, μg/mL | 2.4 (1.3–4.4) | 2.6 (1.8–7.1) | 1.6 (0.6–3.5) | 0.071 |
| Ferritin | ||||
| Baseline, ng/mL | 846.0 (252.3–1614.0) | 658.0 (256.0–994.0) | 1477.0 (217.0–2290.0) | 0.290 |
| Peak, ng/mL | 1375.0 (413.8–2618.8) | 716.0 (404.0–2432.0) | 1866.0 (545.0–3299.0) | 0.130 |
| Prior to CTPA, ng/mL | 668.0 (277.5–1184.5) | 658.0 (267.0–932.0) | 764.0 (281.0–2409.0) | 0.330 |
| Platelets | ||||
| Baseline, 103/μL | 216.0 (171.3–315.5) | 298.0 (181.0–338.0) | 184.0 (165.0–256.0) | 0.034 |
| Peak, 103/μL | 381.0 (297.8–492.5) | 350.0 (297.0–489.0) | 405.0 (319.0–519.0) | 0.372 |
| Prior to CTPA, 103/μL | 288.0 (254.8–381.0) | 292.0 (272.0–310.0) | 280.0 (245.0–390.0) | 1.000 |
| Lymphocytes | ||||
| Baseline, 103/μL | 0.96 (0.6–1.27) | 1.05 (0.59–1.29) | 0.95 (0.6–1.23) | 0.820 |
| Peak*, 103/μL | 0.5 (0.4–0.9) | 0.5 (0.4–1.0) | 0.6 (0.4–0.8) | 0.983 |
| Prior to CTPA, 103/μL | 1.4 (0.8–1.7) | 1.0 (0.7–1.5) | 1.6 (1.0–2.0) | 0.093 |
| NLR | ||||
| Baseline | 7.1 (3.8–10.8) | 7.6 (4.5–10.8) | 5.3 (3.8–11.9) | 0.494 |
| Peak | 13.6 (5.7–22.8) | 15.9 (9.9–26.7) | 12.2 (4.6–22.7) | 0.604 |
| Prior to CTPA | 4.6 (1.8–8.0) | 5.0 (2.6–10.9) | 2.8 (1.6–7.7) | 0.101 |
| IL-6, pg/mL | 59.0 (21.6–156.0) | 36.0 (20.7–89.4) | 59.5 (41.2–225.6) | 0.409 |
| NT-pro BNP, pg/mL | 190.5 (97.5–3353) | 273.0 (139.0–851.0) | 108.0 (89.0–284.0) | 0.106 |
| hs Troponin I, ng/L | 6.0 (3.6–16.2) | 9.2 (5.0–18.7) | 4.2 (3.0–15.4) | 0.135 |
| Fibrinogen, mg/dL | 592.0 (399.8–785.5) | 616.0 (390.0–824.0) | 523.0 (401.0–733.0) | 0.494 |
Values represent median (IQR). Baseline, first variable value; Peak, maximum value; Peak*, minimum value; Previous to CTPA, previous value to CTPA. Abbreviations: CTPA, computed tomography pulmonary angiography; LDH, lactate dehydrogenase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; NT-proBNP, N-terminal pro hormone B-type natriuretic peptide; NLR, neutrophil-to-lymphocyte ratio.